

Table S1: Patients tested by any malaria diagnostic test

Study (by setting)	Without mRDT interventions Percentage Numerator/denominator	With mRDT interventions Percentage Numerator/denominator	Odds Ratio (95% CI)
Afgh1/a ¹	NA	NA	NA
Afgh1/b ¹	NA	NA	NA
Afgh1/c ¹	NA	NA	NA
Afgh2/a	0 0/607	98.8 724/733	∞^2
Afgh2/b	0 0/594	100 466/466	∞^2
Cam1/a ³	78.3 313/400	(1): 70.7 494/699 (2): 79.5 617/776	(1): 0.67 (0.17, 2.66) (2): 1.08 (0.28, 4.1)
Cam1/b ³	80.4 226/281	(1): 81.0 757/933 (2): 77.8 692/889	(1): 1.04 (0.23, 4.7) (2): 0.85 (0.15, 4.7)
Ghan1/a ¹	NA	NA	NA
Ghan1/b ¹	NA	NA	NA
Nige1 ⁴	1.7 27/1,634	(1): 29.9 472/1,576 (2): 23.2 428/1,844 (3): 15.8 237/1,502	(1): 25.5 (7.5, 86) (2): 18.0 (5.0, 64) (3): 11.2 (3.08, 40)
Tanz1/a	7.3 50/689	48.4 363/750	12.0 (4.2, 34.6)
Tanz1/b	12.7 71/559	43.1 167/387	5.2 (2.26, 12.0)
Tanz1/c	31.3 156/498	71.5 409/572	5.5 (2.30, 13.2)
Tanz2 ⁵	0 0/16,068	(1): 39.1 5,556/14,216 (2): 39.7 6,332/15,931 (3): 40.6 5,673/13,972	∞^2

Deleted: 1.00%

Deleted: --

Deleted: --

Deleted: ²

Deleted: ²




Deleted: ³

Deleted: (1): 1.00%
--
%

Deleted: (2): 1.00%
--

Deleted: ⁴

Deleted: (3): 1.00%
--

Uga1	7.3 15,285/210,758	52.9 117,350/221,755	14.4 (6.1, 33.9)
Uga2/a	0 0/10,625	96.0 1,150/1,198	
Uga2/b	0 0/2,444	98.7 7,736/7,840	
Uga3	0 0/8,109	97.3 10,078/10,357	

¹Afgh1 and Ghan1 studies individually randomized patients to malaria diagnostic method and are not included in this analysis.

²Odds ratio undefined; approaches infinity.

³Cam1/a and Cam1/b each had two interventions: (R1) mRDTs supplied with basic training, and (R2) mRDTs supplied with enhanced training.

⁴Nige1 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training plus school-based activities.

⁵Tanz2 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training plus patient sensitization.

Deleted: 1.00%

Deleted: --

Deleted: 1.00%

Deleted: --

Deleted: 1.00%

Deleted: --

Deleted: ¶

Deleted: ²

Deleted: ³

Deleted: ⁴

Table S2: Patients under age five years tested by any malaria diagnostic test

Study (by setting)	Without mRDT interventions Percentage Numerator/denominator	With mRDT interventions Percentage Numerator/denominator	Odds Ratio (95% CI)
Afgh1/a ¹	NA	NA	NA
Afgh1/b ¹	NA	NA	NA
Afgh1/c ¹	NA	NA	NA
Afgh2/a	0.0 0/47	100.0 76/76	∞^2
Afgh2/b	0.0 0/20	100.0 15/15	∞^2
Cam1/a ³	85.2 109/128	(1): 64.4 116/680 (2): 81.2 190/234	(1): 0.32 (0.04, 2.42) (2): 0.75 (0.12, 4.7)
Cam1/b ³	85.2 92/108	(1): 84.0 352/419 (2): 77.4 291/376	(1): 0.91 (0.18, 4.7) (2): 0.60 (0.09, 3.85)
Ghan1/a ¹	NA	NA	NA
Ghan1/b ¹	NA	NA	NA
Nige1 ⁴	2.0 6/299	(1): 32.8 38/116 (2): 30.9 43/139 (3): 27.7 38/137	(1): 23.8 (5.46, 103) (2): 21.9 (4.96, 96.5) (3): 18.7 (3.27, 107)
Tanz1/a	3.5 14/405	50.4 259/514	28.4 (7.9, 102)
Tanz1/b	10.7 33/308	40.5 100/247	5.7 (2.41, 13.3)
Tanz1/c	32.2 103/320	72.2 268/371	5.48 (2.16, 13.9)
Tanz2 ⁵	0.0 0/6,559	(1): 37.7 1,981/5,270 (2): 38.5 2,346/6,101 (3): 39.1	∞^2

Deleted: --

Deleted: --

Deleted: ²

Deleted: ²

Deleted: ³

Deleted:

Deleted: (1): 1.00¶

--

Deleted: (2): 1.00




Deleted: --

Deleted: ⁴

Deleted: (3): 1.00¶

Deleted: ∞

Deleted: --

		1,820/4,649	
Uga1	8.9 5,774/64,825	61.0 40,978/67,159	16.0 (6.1, 42)
Uga2/a	0.0 0/2,444	96.0 1,150/1,198	
Uga2/b	0.0 0/10,625	98.7 7,736/1,198	
Uga3	0.0 0/2,761	98.3 3,829/3,895	

¹Afgh1 and Ghan1 studies individually randomized patients to malaria diagnostic method and are not included in this analysis.

²[Odds ratio undefined; approaches infinity.](#)

³Cam1/a and Cam1/b each had two interventions: (R1) mRDTs supplied with basic training, and (R2) mRDTs supplied with enhanced training.

⁴Nige1 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training plus school-based activities.

⁵Tanz2 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training plus patient sensitization.

Deleted: 1.00%

Deleted: --

Deleted: 1.00%

Deleted: --

Deleted: 1.00%

Deleted: --

Deleted: ²

Deleted: ³

Deleted: ⁴

Table S3: Patients ages five years and older tested by any malaria diagnostic test

Study (by setting)	Without mRDT interventions Percentage Numerator/denominator	With mRDT interventions Percentage Numerator/denominator	Odds Ratio (95% CI)
Afgh1/a ¹	NA	NA	NA
Afgh1/b ¹	NA	NA	NA
Afgh1/c ¹	NA	NA	NA
Afgh2/a	0.0 0/558	98.6 633/642	∞^2
Afgh2/b	0.0 0/573	100.0 449/449	∞^2
Cam1/a ³	75.0 204/272	(1): 72.8 378/519 (2): 78.8 427/542	(1): 0.89 (0.28, 2.90) (2): 1.24 (0.37, 4.1)
Cam1/b ³	77.5 134/173	(1): 78.6 403/513 (2): 78.2 401/513	(1): 1.07 (0.24, 4.7) (2): 1.04 (0.20, 5.5)
Ghan1/a ¹	NA	NA	NA
Ghan1/b ¹	NA	NA	NA
Nige1 ⁴	1.5 20/1,306	(1): 29.5 424/1,438 (2): 22.3 375/1,679 (3): 14.3 191/1,336	(1): 26.9 (7.3, 99) (2): 18.5 (4.8, 71) (3): 10.7 (2.85, 40)
Tanz1/a	12.7 36/284	44.1 104/236	5.4 (1.77, 16.6)
Tanz1/b	15.1 38/251	47.9 67/140	5.1 (1.92, 13.8)
Tanz1/c	29.8 53/178	70.1 141/201	5.5 (2.21, 13.9)
Tanz2 ⁵	0.0 0/9,429	(1): 40.0 3,572/8,926 (2): 40.6 3,975/9,787 (3): 41.4 3,849/9,301	∞^2

Deleted: 1.00¶

Deleted: --

Deleted: --

Deleted: ²

Deleted: ²

Deleted: ³

Deleted:


Deleted: (1): 1.00¶
--
¶

Deleted: (2): 1.00

Deleted: --

Deleted: ⁴

Deleted: (3): 1.00¶
--

Uga1	6.5 9,298/143,834	49.9 74,313/148,980	14.4 (6.23, 33.3)
Uga2/a	NA	NA	NA
Uga2/b	NA	NA	NA
Uga3	0.0 0/5,625	96.7 6,156/6,369	

¹Afgh1 and Ghan1 studies individually randomized patients to malaria diagnostic method and are not included in this analysis.

²[Odds ratio undefined; approaches infinity.](#)

³Cam1/a and Cam1/b each had two interventions: (R1) mRDTs supplied with basic training, and (R2) mRDTs supplied with enhanced training.

⁴Nige1 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training plus school-based activities.

⁵Tanz2 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training plus patient sensitization.

Deleted: 1.00%

Deleted: --

Deleted: ²

Deleted: ³

Deleted: ⁴

Table S4: Patients prescribed ACT¹

Study (by setting)	Without mRDT interventions Percentage Numerator/denominator	With mRDT interventions Percentage Numerator/denominator	Odds Ratio (95% CI)
Afgh1/a	42.0 843/2,005	36.1 740/2,048	0.78 (0.68, 0.90)
Afgh1/b	24.4 126/517	20.1 106/527	0.78 (0.54, 1.13)
Afgh1/c	87.6 283/323	34.7 114/329	0.07 (0.02, 0.25)
Afgh2/a	77.9 471/605	26.6 188/708	0.10 (0.04, 0.25)
Afgh2/b	95.9 567/591	0.6 3/463	0.00 (0.00, 0.00)
Cam1/a ²	79.5 314/395	(1): 43.5 294/676	(1): 0.20 (0.06, 0.61)
		(2): 37.9 286/754	(2): 0.16 (0.05, 0.52)
Cam1/b ²	69.8 194/278	(1): 55.1 496/900	(1): 0.53 (0.28, 1.02)
		(2): 46.5 408/877	(2): 0.38 (0.17, 0.84)
Ghan1/a	63.7 1,210/1,900	62.3 1,180/1,893	0.94 (0.83, 1.08)
Ghan1/b	91.6 1,577/1,722	69.0 1,188/1,721	0.20 (0.07, 0.62)
Nige1 ²	56.9 934/1,642	(1): 49.3 717/1,453	(1): 0.74 (0.40, 1.35)
		(2): 45.4 828/1,823	(2): 0.63 (0.38, 1.03)
		(3): 54.2 808/1,409	(3): 0.90 (0.51, 1.57)
Tanz1/a ³	20.1 138/688	8.5 64/750	0.37 (0.17, 0.79)
Tanz1/b ³	49.2 275/559	25.5 99/388	0.35 (0.20, 0.61)
Tanz1/c ³	57.0 284/498	35.1 201/572	0.41 (0.24, 0.68)
Tanz2 ⁴	43.6 7,008/16,068	(1): 15.8 2,246/14,217	(1): 0.24 (0.15, 0.40)

		(2): 11.6 1,846/15,931	(2): 0.17 (0.10, 0.28)
		(3): 9.5 1,329/13,973	(3): 0.14 (0.08, 0.22)
Uga1	53.8 113,411/210,758	50.8 112,673/221,755	0.89 (0.67, 1.19)
Uga2/a	95.1 2,310/2,428	8.2 94/1,149	0.00 (0.00, 0.01)
Uga2/b	99.2 10,500/10,589	45.7 3,512/7,677	0.01 (0.00, 0.01)
Uga3	99.1 7,981/8,055	60.0 5,933/9,987	0.01 (0.01, 0.04)
<p>¹Table presents the percentage of patients prescribed ACT except for: Afgh1 and Afgh2, where the percentage prescribed all antimalarials is presented to account for <i>P. vivax</i> treatment; and Nige1 without mRDT interventions only, where ACT or sulfadoxine-pyrimethamine (SP) is presented to reflect treatment policy at the time of data collection.</p> <p>²Cam1/a and Cam1/b each had two interventions: (R1) mRDTs supplied with basic training, and (R2) mRDTs supplied with enhanced training.</p> <p>³Nige1 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training plus school-based activities.</p> <p>⁴ACTs obtained by patient at the consultation (ACTs prescribed not available).</p> <p>⁵Tanz2 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training plus patient sensitization.</p>			

Table S5: Patients in scenarios with mRDT interventions prescribed ACT, by malaria test result and not tested

Study (by setting)	Percentage patients prescribed an ACT (95% CI) Numerator / denominator			
	Positive test result	Negative test result	Not tested	
Afgh1/a ^{1,2,3}	99.5 (97.9, 99.9) 552/555	12.6 (5.1, 27.7) 188/1,493	NA	
Afgh1/b ^{1,2,3}	--	19.2 (1.7, 76.0) 100/521	NA	
Afgh1/c ^{1,2,3}	--	34.5 (8.4, 75.1) 113/328	NA	
Afgh2/a ^{1,3}	82.7 (63.3, 93.0) 163/197	4.0 (1.7, 9.2) 20/503	--	
Afgh2/b ^{1,3}	--	0.4 (0.1, 1.3) 2/459	--	
Cam1/a ⁴	(1): 70.2 (37.3, 90.3) 33/47	(1): 39.2 (13.4, 72.8) 167/426	(1): 45.2 (28.7, 62.7) 89/197	
	(2): 79.6 (62.1, 90.3) 117/147	(2): 24.6 (7.4, 57.2) 110/447	(2): 35.3 (6.1, 82.0) 54/153	
Cam1/b ⁴	(1): 72.4 (58.2, 83.1) 254/351	(1): 42.5 (29.3, 56.9) 157/369	(1): 48.5 (40.5, 56.6) 81/167	
	(2): 70.1 (54.6, 82.0) 246/351	(2): 18.3 (8.8, 34.2) 57/312	(2): 51.6 (28.6, 73.9) 99/192	
Ghan1/a ²	98.2 (96.7, 99.0) 584/595	45.9 (43.2, 48.6) 596/1,298	(1): 45.0 (29.1, 61.9) 453/1,007	
			(2): 48.2 (38.3, 58.2) 674/1,399	
			(3): 56.9 (46.1, 67.1) 710/1,248	
Ghan1/b ²	97.5 (88.0, 99.5) 692/710	49.1 (1.0, 98.9) 496/1,011	NA	
Nige1 ⁵	(1): 74.4 (68.3, 79.6) 238/320	(1): 21.4 (10.3, 39.3) 24/112	NA	
				(2): 66.9 (48.4, 81.3) 95/142
				(3): 60.2 (40.3, 77.2) 59/98
Tanz1/a ⁶	18.2 (7.0, 39.7)	4.9 (2.5, 9.6)	9.3 (4.9, 17.1)	

	14/77	14/283	36/387
Tanz1/b ⁶	94.4 (56.6, 99.5) 17/18	13.4 (8.1, 21.4) 20/149	28.2 (18.3, 40.8) 62/220
Tanz1/c ⁶	68.2 (53.4, 80.1) 131/192	5.1 (1.9, 12.9) 11/217	36.2 (17.3, 60.7) 59/163
Tanz2 ⁷	(1): 78.8 (64.6, 88.3) 1,146/1,455 (2): 80.2 (65.2, 89.8) 1,361/1,696 (3): 75.6 (50.3, 90.4) 944/1,249	(1): 17.0 (10.7, 26.0) 685/4,024 (2): 4.2 (1.8, 9.7) 191/4,541 (3): 3.6 (1.6, 8.2) 157/4,332	(1): 4.6 (2.2, 9.6) 401/8,660 (2): 3.0 (1.2, 7.0) 286/9,599 (3): 2.6 (1.2, 5.7) 218/8,299
Uga1	93.2 (89.7, 95.5) 75,808/81,359	2.7 (2.1, 3.5) 977/35,711	34.2 (23.1, 47.3) 35,717/104,405
Uga2/a	66.7 (41.7, 84.8) 24/36	3.1 (1.4, 6.4) 32/1,041	69.6 (48.7, 84.6) 32/46
Uga2/b	98.0 (96.9, 98.7) 3,318/3,385	1.1 (0.6, 1.8) 43/4,067	93.1 (80.4, 97.8) 95/102
Uga3	97.9 (96.5, 98.7) 5,551/5,670	1.2 (0.8, 1.9) 47/3,868	96.4 (91.4, 98.5) 269/279

¹Table presents the percentage of patients in scenarios with mRDT interventions prescribed ACT except for Afgh1 and Afgh2, where the percentage prescribed all antimalarials is presented to account for *P. vivax* treatment.

²Patients in the Afgh1 and Ghan1 studies were individually randomized to malaria diagnostic method; data are not included in this analysis since all patients in scenarios with mRDT interventions were tested.

³Data not included in the analysis when denominators were less than 10.

⁴Cam1/a and Cam1/b each had two interventions: (R1) mRDTs supplied with basic training, and (R2) mRDTs supplied with enhanced training.

⁵Nige1 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training plus school-based activities.

⁶ACTs obtained by patient at the consultation; data on ACTs prescribed not available in Tanz1.

⁷Tanz2 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training plus patient sensitization.

Table S6: Patients prescribed a systemic antibacterial

Study (by setting)	Without mRDT interventions Percentage Numerator/denominator	With mRDT interventions Percentage Numerator/denominator	Odds Ratio (95% CI)
Afgh1/a	38.1 763/2,005	40.8 836/2,048	1.12 (0.97, 1.03)
Afgh1/b	73.3 379/517	78.9 416/527	1.36 (0.76, 2.43)
Afgh1/c	14.2 46/323	57.1 188/329	8.0 (2.70, 23.9)
Afgh2/a	18.2 110/605	54.1 383/708	5.3 (2.28, 12.4)
Afgh2/b	48.4 286/591	68.5 317/463	2.32 (0.85, 6.3)
Cam1/a ¹	72.8 287/394	(1): 78.5 534/680 (2): 78.5 595/757	(1): 1.36 (0.68, 2.84) (2): 1.36 (0.76, 2.43)
Cam1/b1	50.4 140/278	(1): 56.9 510/897 (2): 47.3 415/877	(1): 1.30 (0.48, 3.53) (2): 0.89 (0.35, 2.27)
Ghan1/a	30.8 586/1,900	32.1 608/1,896	1.06 (0.92, 1.21)
Ghan1/b	28.0 483/1,723	32.6 560/1,719	1.24 (0.90, 1.72)
Nige1 ²	23.2 382/1,642	(1): 13.6 199/1,467 (2): 18.2 330/1,817 (3): 15.1 223/1,474	(1): 0.52 (0.29, 0.93) (2): 0.73 (0.46, 1.17) (3): 0.59 (0.34, 1.03)
Tanz1/a ³	29.7 204/688	44.7 335/749	1.92 (1.20, 3.08)
Tanz1/b ³	35.2 197/688	56.4 219/388	2.38 (1.54, 3.68)
Tanz1/c ³	33.1 165/498	49.0 280/572	1.94 (1.32, 3.83)
Tanz2 ⁴	61.5 9875/16,068	(1): 73.2 10,407/14,217	(1): 1.71 (1.25, 2.35)

		(2): 75.4 12,014/15,931	(2): 1.92 (1.42, 2.61)
		(3): 70.5 9,853/13,973	(3): 1.50 (1.19, 1.89)
Uga1	53.7 113,102/210,758	57.9 128,406/221,755	1.18 (0.79, 1.77)
Uga2/a ⁵	NA	NA	NA
Uga2/b ⁵	NA	NA	NA
Uga3	19.4 48/248	34.9 87/249	2.24 (1.41, 3.54)
<p>¹Cam1/a and Cam1/b each had two interventions: (R1) mRDTs supplied with basic training, and (R2) mRDTs supplied with enhanced training.</p> <p>²Nige1 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training plus school-based activities.</p> <p>³Any antibacterials obtained by patients at the consultation; data on systemic antibacterials prescribed not available in Tanz1.</p> <p>⁴Tanz2 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training plus patient sensitization.</p> <p>⁵Community health workers in Uga2 were not permitted to prescribe antibacterials medicines, so this study is not included in this analysis.</p>			

Table S7: Patients in scenarios with mRDT interventions prescribed a systemic antibacterial, by malaria test result and not tested

Study (by setting)	Percentage prescribed an antibacterial (95% CI) Numerator / denominator		
	Positive test result	Negative test result	Not tested
Aghg1/a ¹	3.6 (1.8, 7.1) 20/555	54.7 (37.9, 70.4) 816/1,493	NA
Afgh1/b ^{1,2}	--	70.7 (60.0, 91.1) 415/521	NA
Afgh1/c ^{1,2}	--	57.3 (23.0, 85.8) 188/328	NA
Afgh2/a ²	8.1 (4.8, 13.5) 16/197	72.8 (49.9, 87.8) 366/503	---
Afgh2/b ²	--	68.8 (41.9, 87.1) 316/459	---
Cam1/a ³	(1): 66.0 (48.2, 80.1) 31/47	(1): 79.9 (65.9, 89.1) 341/427	(1): 80.0 (57.5, 92.2) 160/200
	(2): 74.7 (65.3, 82.2) 109/146	(2): 83.1 (75.4, 88.9) 375/451	(2): 69.3 (64.6, 73.6) 106/153
Cam1/b ³	(1): 58.0 (42.4, 72.2) 203/350	(1): 63.5 (46.9, 77.4)	(1): 42.5 (25.2, 61.9) 71/167
	(2): 43.7 (31.7, 56.5) 153/350	(2): 52.6 (45.1, 60.0) 164/312	(2): 47.9 (28.2, 68.3) 92/192
Ghan1/a ¹	14.6 (12.0, 17.7) 87/595	40.0 (37.4, 42.7) 521/1,301	NA
Ghan1/b ¹	18.0 (11.1, 27.9) 128/710	42.8 (12.4, 79.9) 432/1,009	NA
Nige1 ⁴	(1): 17.5 (13.3, 22.7) 55/314	(1): 26.1 (12.2, 47.4) 29/111	(1): 11.1 (5.6, 20.9) 114/1,026
	(2): 14.9 (8.5, 24.7) 21/141	(2): 13.3 (6.7, 24.6) 37/279	(2): 19.5 (14.9, 25.2) 271/1,388
	(3): 20.2 (8.5, 41.0) 20/99	(3): 21.6 (13.9, 32.2) 29/134	(3): 13.9 (8.9, 21.3) 172/1,233
Tanz1/a ⁵	31.6 (17.3, 50.5) 24/76	53.0 (42.2, 63.6) 150/283	41.3 (30.4, 52.2) 160/387
Tanz1/b ⁵	44.4 (11.4, 83.3) 8/18	58.4 (47.2, 68.8) 87/149	56.4 (44.7, 67.4) 124/220
Tanz1/c ⁵	30.7 (20.8, 42.9) 59/192	61.8 (50.4, 71.9) 134/217	53.4 (39.4, 66.8) 87/163
Tanz2 ⁶	(1): 26.5 (13.4, 45.8)	(1): 74.2 (67.1, 80.2)	(1): 80.6 (75.5, 84.8)

	386/1,455 (2): 36.1 (25.4, 48.3) 612/1,696 (3): 26.3 (18.0, 36.6) 328/1,249	2,985/4,024 (2): 77.7 (69.9, 83.9) 3,527/4,541 (3): 74.7 (69.2, 79.6) 3,238/4,332	6,979/6,880 (2): 81.3 (75.1, 86.2) 7,800/9,599 (3): 74.9 (68.6, 80.3) 6,214/8,299
Uga1	40.5 (30.6, 51.2) 32,935/81,359	69.3 (65.3, 73.0) 24,737/35,711	66.3 (60.5, 71.7) 69,178/104,405
Uga2/a ⁷	NA	NA	NA
Uga2/b ⁷	NA	NA	NA
Uga3 ²	23.6 (16.3, 33.0) 30/127	46.0 (37.7, 54.6) 52/113	---
<p>¹Patients in the Afgh1 and Ghan1 studies were individually randomized to malaria diagnostic method; data are not included in this analysis since all patients in scenarios with mRDT interventions were tested.</p> <p>²Data not included in the analysis when denominators were less than 10.</p> <p>³Cam1/a and Cam1/b each had two interventions: (R1) mRDTs supplied with basic training, and (R2) mRDTs supplied with enhanced training.</p> <p>⁴Nige1 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training plus school-based activities.</p> <p>⁵Any antibacterials obtained by patients at the consultation; data on systemic antibacterials prescribed not available in Tanz1.</p> <p>⁶Tanz2 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training plus patient sensitization.</p> <p>⁷Community health workers in Uga2 were not permitted to prescribe antibacterials medicines, so this study is not included in this analysis.</p>			

Table S8: Patients prescribed an antimalarial and an antibacterial

Study (by setting)	Without mRDT interventions Percentage Numerator/denominator	With mRDT interventions Percentage Numerator/denominator	Odds Ratio (95% CI)
Afgh1/a	1.2 25/2,005	1.5 30/2,048	1.18 (0.66, 2.11)
Afgh1/b	10.6 55/517	8.7 46/527	0.80 (0.54, 1.19)
Afgh1/c	4.6 15/323	4.3 14/329	0.91 (0.50, 1.68)
Afgh2/a	47.4 280/51	0.2 1/463	0.00 (0.00, 0.02)
Afgh2/b	16.7 101/605	3.1 22/708	0.16 (0.06, 0.40)
Cam1/a ¹	66.1 259/392	(1): 37.7 253/672	(1): 0.31 (0.15, 0.65)
		(2): 32.8 247/753	(2): 0.25 (0.10, 0.61)
Cam2/b ¹	43.9 122/278	(1): 40.1 359/896	(1): 0.85 (0.33, 2.24)
		(2): 28.1 247/875	(2): 0.50 (0.19, 1.31)
Ghan1/a	12.3 234/1,899	12.4 235/1,893	1.01 (0.83, 1.22)
Ghan1/b	23.8 410/1,722	15.3 263/1,719	0.58 (0.32, 1.04)
Nige1 ²	14.7 241/1,642	(1): 12.3 174/1,459	(1): 0.81 (0.48, 1.39)
		(2): 14.0 253/1,805	(2): 0.95 (0.58, 1.55)
		(3): 11.9 175/1,472	(3): 0.78 (0.51, 1.21)
Tanz1/a ³	6.8 47/688	4.1 31/749	0.59 (0.27, 1.28)
Tanz1/b ³	18.2 102/559	12.9 50/388	0.66 (0.36, 1.22)
Tanz1/c ³	15.5 77/498	14.7 84/572	0.94 (0.49, 1.82)
Tanz2 ⁴	24.2 3,891/16,068	(1): 6.9 974/14,217	(1): 0.23 (0.14, 0.37)

		(2): 5.7 908/15,931	(2): 0.19 (0.12, 0.31)
		(3): 3.6 500/13,973	(3): 0.12 (0.07, 0.19)
Uga1	23.8 50,098/210,758	23.5 52,212/221,755	0.99 (0.59, 1.65)
Uga2/a ⁵	NA	NA	NA
Uga2/b ⁵	NA	NA	NA
Uga3	19.4 48/248	14.2 33/233	0.69 (0.45, 1.06)
<p>¹Cam1/a and Cam1/b each had two interventions: (R1) mRDTs supplied with basic training, and (R2) mRDTs supplied with enhanced training.</p> <p>²Nige1 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training plus school-based activities.</p> <p>³Antimalarials and any antibacterials obtained by patients at the consultation; data on medicines prescribed not available in Tanz1.</p> <p>⁴Tanz2 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training plus patient sensitization.</p> <p>⁵Community health workers in Uga2 were not permitted to prescribe antibacterials medicines, so this study is not included in this analysis.</p>			

Table S9: Patients prescribed an antimalarial or an antibacterial

Study (by setting)	Without mRDT interventions Percentage Numerator/denominator	With mRDT interventions Percentage Numerator/denominator	Odds Ratio (95% CI)
Afgh1/a	78.9 1,581/2,005	75.5 1,546/2,048	0.83 (0.74, 0.93)
Afgh1/b	87.0 450/517	90.3 476/527	1.39 (0.73, 2.66)
Afgh1/c	97.2 314/323	87.5 288/329	0.20 0.08, 0.48)
Afgh2/a	97.0 573/591	68.9 319/463	0.07 (0.03, 0.19)
Afgh2/b	79.3 480/605	77.5 549/708	0.90 (0.32, 2.56)
Cam1/a ¹	94.2 372/394	(1): 92.5 629/680	(1): 0.73 (0.19, 2.76)
		(2): 90.9 687/757	(2): 0.59 (0.16, 2.14)
Cam1/b ¹	97.1 270/278	(1): 88.1 790/897	(1): 0.22 (0.10, 0.49)
		(2): 79.8 700/877	(2): 0.12 (0.05, 0.27)
Ghan1/a	82.9 1,575/1,899	82.2 1,557/1,894	0.95 (0.80, 1.12)
Ghan1/b	97.0 1,670/1,722	85.7 1,501/1,719	0.21 (0.10, 0.48)
Nige1 ²	84.5 1,369/1,642	(1): 81.7 1158/1,460	(1): 0.82 (0.37, 1.79)
		(2): 80.4 1,451/1,805	(2): 0.75 (0.41, 1.37)
		(3): 86.8 1,278/1,473	(3): 1.20 (0.49, 2.93)
Tanz1/a ³	46.2 318/688	52.7 395/749	1.30 (0.81, 2.09)
Tanz1/b ³	68.7 384/559	70.4 273/388	1.08 (0.61, 1.93)
Tanz1/c ³	79.1 394/498	72.2 413/572	0.69 (0.40, 1.16)
Tanz2 ⁴	87.9 14,125/16,068	(1): 85.4 12,146/14,217	(1): 0.81 (0.61, 1.08)

		(2): 84.4 13,446/15,931	(2): 0.74 (0.55, 1.01)
		(3): 79.0 11,032/13,973	(3): 0.52 (0.40, 0.66)
Uga1	85.5 180,106/210,758	87.0 192,831/221,755	1.13 (0.67, 1.91)
Uga2/a ⁵	NA	NA	NA
Uga2/b ⁵	NA	NA	NA
Uga3	100.0 248/248	78.7 188/239	0.00⁶

¹Cam1/a and Cam1/b each had two interventions: (R1) mRDTs supplied with basic training, and (R2) mRDTs supplied with enhanced training.

²Nige1 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training plus school-based activities.

³Antimalarials and any antibacterials obtained by patients at the consultation; data on medicines prescribed not available in Tanz1.

⁴Tanz2 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training plus patient sensitization.

⁵Community health workers in Uga2 were not permitted to prescribe antibacterials medicines, so this study is not included in this analysis.

⁶Odds ratio undefined; approaches zero.

Deleted: 1.00[¶]

Deleted: --

Formatted: Superscript

Table S10: Patients prescribed a systemic antihelminthic, and patients prescribed a systemic antifungal

Study (by setting)	Antihelminthics		Antifungals	
	Without mRDT interventions Percentage Numerator/denominator	With mRDT interventions Percentage Numerator/denominator	Without mRDT interventions Percentage Numerator/denominator	With mRDT interventions Percentage Numerator/denominator
Afgh1/a	0.5 (10/2,005)	0.3 (7/2,048)	0 (0/2,005)	0 (0/2,048)
Afgh1/b	0.8 (4/517)	0.8 (4/527)	0 (0/517)	0 (0/527)
Afgh1/c	0.0 (0/323)	0.3 (1/329)	0 (0/323)	0 (0/329)
Afgh2/a ¹	NA	NA	NA	NA
Afgh2/b ¹	NA	NA	NA	NA
Cam1/a ²	11.4 (45/394)	(1): 4.3 (29/680) (2): 8.5 (76/897)	0.8 (3/394)	(1): 1.2 (8/680) (2): 1.9 (17/897)
Cam1/b ²	8.3 (23/278)	(1): 7.1 (54/757) (2): 10.4 (91/877)	1.4 (4/278)	(1): 0.4 (3/757) (2): 2.6 (23/877)
Ghan1/a	31.6 (600/1,900)	33.3 (631/1,896)	0.6 (11/1,900)	0.7 (13/1,896)
Ghan1/b	8.6 (149/1,723)	11.3 (195/1,719)	0.1 (1/1,723)	0.3 (6/1,719)
Nige1 ³	2.0 (33/1,642)	(1): 0.3 (4/1,588) (2): 0.3 (5/1,850) (3): 1.3 (19/1,508)	0.1 (1/1642)	(1): 0 (0/1,588) (2): 0 (0/1,850) (3): 0 (0/1,508)
Tanz1/a ⁴	1.7 (12/688)	4.5 (34/749)	0 (0/688)	0 (0/749)
Tanz1/b ⁴	3.2 (18/559)	7.2 (28/388)	0 (0/559)	0 (0/388)
Tanz1/c ⁴	2.2 (11/498)	3.1 (18/572)	0 (0/498)	0 (0/572)
Tanz2 ¹	NA	(1): NA (2): NA	NA	(1): NA (2): NA

		(3): NA		(3): NA
Uga1	14.6 (30,865/210,758)	16.1 (35,683/221,755)	0.1 (195/210,758)	0.1 (318/221,755)
Uga2/a ¹	NA	NA	NA	NA
Uga2/b ¹	NA	NA	NA	NA
Uga3	4.0 (10/248)	5.2 (13/249)	0 (0/248)	0 (0/249)

¹Data on systemic antihelminthics and antifungals prescribed were not collected from Afgh2, Tanz2, and Uga2.


²Cam1/a and Cam1/b each had two interventions: (R1) mRDTs supplied with basic training, and (R2) mRDTs supplied with enhanced training.

³Nige1 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training plus school-based activities.

⁴Systemic antihelminthics and antifungals obtained by patients at the consultation; data on medicines prescribed not available in Tanz1.

Table S11: Patients prescribed an antipyretic without an antimalarial or an antibiotic

Study (by setting)	Without mRDT interventions Percentage Numerator/denominator	With mRDT interventions Percentage Numerator/denominator	Odds Ratio (95% CI)
Afgh1/a	19.7 395/2,005	22.7 464/2,048	1.19 (1.07, 1.34)
Afgh1/b	10.8 56/517	8.2 43/527	0.73 (0.35, 1.53)
Afgh1/c	2.8 9/323	12.2 40/329	4.8 (2.16, 10.8)
Afgh2/a	1.2 7/591	17.3 80/463	17.4 (3.41, 89)
Afgh2/b	0.3 2/605	11.6 82/708	39.5 (12.9, 121)
Cam1/a ¹	0.5 2/392	(1): 4.2 28/671	(1): 8.5 (1.34, 54)
		(2): 7.1 53/749	(2): 14.9 (2.44, 90)
Cam1/b ¹	1.8 5/278	(1): 3.7 33/895	(1): 2.09 (0.66, 6.7)
		(2): 5.8 51/874	(2): 3.38 (1.01, 11.4)
Ghan1/a	12.6 239/1,899	14.3 271/1,893	1.16 (0.96, 1.40)
Ghan1/b	2.4 42/1,722	10.2 176/1,719	4.6 (1.98, 10.5)
Nige1 ²	7.6 138/1,642	(1): 3.1 44/1,459	(1): 0.39 (0.17, 0.89)
		(2): 8.9 161/1,825	(2): 1.19 (0.66, 2.13)
		(3): 3.9 58/1,489	(3): 0.50 (0.18, 1.39)
Tanz1/a ³	23.7 163/688	18.8 141/749	0.75 (0.46, 1.23)
Tanz1/b ³	12.7 71/559	12.1 47/388	0.95 (0.49, 1.83)
Tanz1/c ³	9.4 47/498	18.2 104/572	2.13 (1.25, 3.64)
Tanz2 ⁴	6.4 (1,020/15,953)	(1): 10.9	(1): 1.78 (1.32, 2.41)

		1,545/14,217 (2): 11.4 1,818/15,931 (3): 14.1 1,964/13,973	(2): 1.89 (1.34, 2.65) (3): 2.39 (1.89, 3.04)
Uga1	10.1 21,803/210,758	8.4 18,630/221,755	0.79 (0.43, 1.45)
Uga2/a ⁵	NA	NA	NA
Uga2/b ⁵	NA	NA	NA
Uga3	0.0 0/248	14.6 34/233	
<p>¹Cam1/a and Cam1/b each had two interventions: (R1) mRDTs supplied with basic training, and (R2) mRDTs supplied with enhanced training.</p> <p>²Nige1 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training plus school-based activities.</p> <p>³Antipyretics obtained by patients at the consultation; data on medicines prescribed not available in Tanz1.</p> <p>⁴Tanz2 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training plus patient sensitization.</p> <p>⁵Community health workers in Uga2 were not permitted to prescribe antibacterials medicines, so this study is not included in this analysis.</p> <p>⁶Odds ratio undefined; approaches infinity.</p>			

Deleted: 1.00%

Deleted: --

Table S12: Patients prescribed three or more medicines

Study (by setting)	Without mRDT interventions Percentage Numerator/denominator	With mRDT interventions Percentage Numerator/denominator	Odds Ratio (95% CI)
Afgh1/a	16.1 322/2,005	15.1 309/2,048	0.93 (0.80, 1.08)
Afgh1/b	36.0 186/517	34.7 183/527	0.95 (0.85, 1.06)
Afgh1/c	60.1 194/323	38.3 126/329	0.41 (0.19, 0.92)
Afgh2/a	62.3 368/591	3.2 15/463	0.02 (0.01, 0.05)
Afgh2/b	28.1 170/605	10.2 72/708	0.29 (0.10, 0.88)
Cam1/a ¹	87.5 350/400	(1): 82.3 575/699	(1): 0.66 (0.28, 1.58)
		(2): 79.8 621/778	(2): 0.57 (0.26, 1.22)
Cam1/b ¹	78.6 221/281	(1): 71.5 667/933	(1): 0.68 (0.33, 1.41)
		(2): 61.3 546/891	(2): 0.43 (0.19, 0.98)
Ghan1/a	91.8 (1,751/1,907)	91.4 (1,740/1,904)	0.95 (0.75, 1.19)
Ghan1/b	90.3 (1,559/1,727)	88.2 (1,521/1,725)	0.80 (0.61, 1.07)
Nige1 ²	60.8 965/1,587	(1): 56.4 896/1,588	(1): 0.83 (0.45, 1.54)
		(2): 53.2 985/1,850	(2): 0.73 (0.39, 1.38)
		(3): 57.1 861/1,508	(3): 0.86 (0.51, 1.44)
Tanz1/a ³	13.8 95/688	18.6 139/748	1.42 (0.80, 2.53)
Tanz1/b ³	24.2 143/498	30.7 119/388	1.39 (0.90, 2.14)
Tanz1/c ³	28.7 143/498	26.6 152/571	0.90 (0.52, 1.57)
Tanz2 ⁴	NA	(1): NA	(1): NA

		(2): NA	(2): NA
		(3): NA	(3): NA
Uga1	50.9 107,348/210,758	52.2 115,850/221,755	1.05 (0.66, 1.68)
Uga2/a ⁵	NA	NA	NA
Uga2/b ⁵	NA	NA	NA
Uga3	54.0 134/248	60.2 150/249	1.29 (0.80, 2.07)

¹Cam1/a and Cam1/b each had two interventions: (R1) mRDTs supplied with basic training, and (R2) mRDTs supplied with enhanced training.

²Nige1 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training plus school-based activities.

³Medicines obtained by patients at the consultation; data on medicines prescribed not available in Tanz1.

⁴Tanz2 did not record data on all medications prescribed, so this study is not included in Figure 4d.

⁵Community health workers in Uga2 were not permitted to prescribe antibacterials medicines, so this study is not included in this analysis.

Table S13: Patients referred to another care provider or health facility

Study (by setting)	Without mRDT interventions Percentage Numerator/denominator	With mRDT interventions Percentage Numerator/denominator	Odds Ratio (95% CI)
Afgh1/a	0.1 3/2,005	0.0 1/2,048	0.33 (0.03, 3.47)
Afgh1/b	0.0 0/323	0.0 0/329	--
Afgh1/c	0.2 1/517	0.4 2/527	1.97 (0.13, 29.1)
Afgh2/a	29.0 172/594	64.2 299/466	4.4 (2.28, 8.5)
Afgh2/b	23.9 145/607	15.7 115/732	0.59 (0.19, 1.81)
Cam1 ¹	0.8 3/399	(1): 0.9 6/695	(1): 1.15 (0.28, 4.7)
		(2): 1.4 11/769	(2): 1.92 (0.47, 7.8)
Cam2 ¹	0.4 1/280	(1): 1.3 12/903	(1): 3.76 (0.70, 20.1)
		(2): 3.5 30/864	(2): 10.0 (1.38, 73)
Ghan1/a ²	NA	NA	NA
Ghan1/b ²	NA	NA	NA
Nige1 ³	1.0 17/1,630	(1): 1.9 30/1,548	(1): 1.88 (0.59, 5.9)
		(2): 1.7 31/1,833	(2): 1.63 (0.61, 4.4)
		(3): 3.8 57/1,491	(3): 3.77 (0.89, 15.93)
Tanz1/a ²	NA	NA	NA
Tanz1/b ²	NA	NA	NA
Tanz1/c ²	NA	NA	NA
Tanz2 ^{2,4}	NA	(1): NA	(1): NA
		(2): NA	(2): NA
		(3): NA	(3): NA
Uga1 ²	NA	NA	NA
Uga2/b	1.0	35.1	52

	109/10,599	821/1,168	(34.8, 77)
Uga2/a	13.1 314/2,404	70.3 2,706/77,16	15.8 (9.3, 27)
Uga3	3.5 279/8,039	12.1 1,234/10,226	3.82 (0.82, 17.8)

¹Cam1/a and Cam1/b each had two interventions: (R1) mRDTs supplied with basic training, and (R2) mRDTs supplied with enhanced training.

²Ghan1, Tanz1, Tanz2, and Uga1 did not record data on referral.

³Nige1 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training plus school-based activities.

⁴Tanz2 had three interventions: (R1) mRDTs supplied with basic training, (R2) mRDTs supplied with enhanced training, and (R3) mRDTs supplied with enhanced training plus patient sensitization.